Eli Lilly and (NYSE:LLY) had its price objective increased by research analysts at BMO Capital Markets from $73.00 to $74.00 in a report issued on Thursday. The brokerage presently has an “underperform” rating on the stock. BMO Capital Markets’ price target would indicate a potential downside of 10.21% from the company’s previous close.
LLY has been the subject of a number of other reports. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price target for the stock from $84.23 to $88.00 in a research note on Tuesday, October 10th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a report on Thursday, October 26th. Morgan Stanley increased their price objective on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 21st. Cowen restated a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a research report on Wednesday, October 4th. Finally, Berenberg Bank reiterated a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research report on Thursday, October 26th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $92.13.
Shares of Eli Lilly and (NYSE LLY) traded up $0.96 during trading hours on Thursday, reaching $82.41. 8,410,293 shares of the company traded hands, compared to its average volume of 3,880,000. Eli Lilly and has a one year low of $76.55 and a one year high of $89.09. The stock has a market capitalization of $90,740.00, a price-to-earnings ratio of -412.05, a PEG ratio of 1.67 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Susan Mahony sold 36,585 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Insiders sold 251,088 shares of company stock valued at $22,041,236 in the last three months. 0.20% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of LLY. Janus Henderson Group PLC raised its holdings in Eli Lilly and by 7,093.5% in the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after acquiring an additional 9,223,251 shares in the last quarter. Dodge & Cox raised its holdings in Eli Lilly and by 22,094.9% during the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after purchasing an additional 5,964,955 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Eli Lilly and by 91.1% during the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after purchasing an additional 2,714,505 shares in the last quarter. Bank of Montreal Can raised its holdings in Eli Lilly and by 85.4% during the fourth quarter. Bank of Montreal Can now owns 4,631,241 shares of the company’s stock worth $391,156,000 after purchasing an additional 2,133,606 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Eli Lilly and by 2.3% during the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after purchasing an additional 1,610,885 shares in the last quarter. 76.53% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by American Banking and Market News and is the sole property of of American Banking and Market News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/01/eli-lilly-and-lly-given-new-74-00-price-target-at-bmo-capital-markets.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
